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Abstract
While genetic polymorphisms play a paramount role in tuberculosis (TB), less is known about their contribution to the severity of diseases
caused by other intracellular bacteria and fastidious microorganisms. We searched electronic databases for observational studies reporting
on host factors and genetic predisposition to infections caused by intracellular fastidious bacteria published up to 30 May 2014. The
contribution of genetic polymorphisms was documented for TB. This includes genetic defects in the mononuclear phagocyte/T helper cell
type 1 (Th1) pathway contributing to disseminated TB disease in children and genome-wide linkage analysis (GWAS) in reactivated
pulmonary TB in adults. Similarly, experimental studies supported the role of host genetic factors in the clinical presentation of illnesses
resulting from other fastidious intracellular bacteria. These include IL-6 -174G/C or low mannose-binding (MBL) polymorphisms, which are
incriminated in chronic pulmonary conditions triggered by C. pneumoniae, type 2-like cytokine secretion polymorphisms, which are
correlated with various clinical patterns of M. pneumoniae infections, and genetic variation in the NOD2 gene, which is an indicator of tubal
pathology resulting from Chamydia trachomatis infections. Monocyte/macrophage migration and T lymphocyte recruitment defects are
corroborated to ineffective granuloma formation observed among patients with chronic Q fever. Similar genetic polymorphisms have also
been suggested for infections caused by T. whipplei although not confirmed yet. In conclusion, this review supports the paramount role of
genetic factors in clinical presentations and severity of infections caused by intracellular fastidious bacteria. Genetic predisposition should be
further explored through such as exome sequencing.
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Introduction
Infections caused by intracellular bacteria and fastidious organ-
isms such as Chlamydia, Mycoplasma and Coxiella burnetii are
associated with important morbidities [1]. Although most of
these infections are prevalent worldwide [2], variability in
prevalence may be related to ecological vectors such as ticks
and mosquitoes for diseases caused by Rickettsiae or Tulare-
mia. Socio-demographical factors such as farming and close
contact with animals are also important risk factors as
documented in multiple outbreaks of C. burnetii infections
reported after close exposure to animals in the Netherlands
between 2007 and 2011 [3] and more recently in Switzerland
[4]. Variability in the clinical expression may also result from
bacterial virulence factors present in a given strain, the extent of
exposure (inoculum) or host factors such as genetic suscepti-
bility. Likewise, variability in morbidities and mortality can be
explained by socio-economic factors, mainly access to medical
facilities, which has a direct impact on time to diagnosis and
treatment. Transmission route and host factors such as genetic
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susceptibility may also be important. While the contribution of
socio-demographic factors and arthropod or animal vectors to
infections caused by intracellular bacteria and fastidious organ-
isms is well documented, less is known about the role of host
factors such as genetic polymorphisms. Thus, this review will
specifically focus on genetic susceptibility to infections caused
by intracellular bacteria and fastidious organisms.
Literature Search
We included observational studies reporting on host factors
and genetic susceptibility to infections caused by intracellular
organisms and fastidious bacteria such as chlamydiae (C. tra-
chomatis, C. psittaci and C. pneumoniae), M. pneumoniae, C. bur-
netii and T. whipplei. In addition, observational studies focusing
on human genetics of tuberculosis were included as host factor
susceptibility to Mycobacterium tuberculosis infections was
extensively described. Given the complexity of human genetics
of tuberculosis and the recent publication of an extensive
review [5], we will provide a brief overview of genetic
susceptibility to mycobacterial infections
Practically, we searched MEDLINE and EMBASE for relevant
studies published in any year or in any language up to 30 May
2014. We also reviewed references listed in key articles. More
than 150 unique records were initially identified through our
literature search (Table 1).
Mycobacterium tuberculosis
Tuberculosis remains a major public health problem, with
8.7 million new cases diagnosed each year [6,7]. Although
one-third of the world’s population is exposed to TB, not all
the individuals will become infected. Among those infected,
only about 5% will develop clinical disease, thus strongly
suggesting the role of underlying genetic factors in TB. The
observations of increased prevalence of extra-pulmonary
tuberculosis among non-Caucasian populations [8] and
increased concomittant rates of TB disease among monozy-
gote twins (60%) vs dizygotes twins (35%) [9] support a major
role for human genetic factors in the development of TB
(Table 2). Recent documentation of high variability rates of
tuberculin skin test (TST) responsiveness and quantitative
Interferon Gamma Release Assay (IGRA) reactivity following
exposure to active TB cases in healthy children [10,11]
supports the role of host factors. Genetic polymorphism may
have an impact on the type of histopathological lesions
observed (granuloma vs disseminated disease) as well as on
clinical disease (pulmonary vs extrapulmonary disease) and
morbidity rates.
Genetic variants correlated with susceptibility to TB include
Il10 promoter haplotypes and genome-wide linkage analysis
(GWAS). Increased rates of an Il10 promoter haplotype
resulting in low levels of circulating Il-10 were documented
among TST-positive subjects compared with TST-negative
ones [12], whereas GWAS correlated specific chromosomal
regions (2q21-2q24 and 5p13-5q22) with persistent TST
negativity [13].
While severe primary TB commonly occurs in children
under 2 years of age, only a minority of infected children will
develop severe clinical forms, thus supporting the role of single
inborn errors of immunity. Indeed, monogenic Mendelien
defects in the mononuclear phagocyte/T helper cell type 1
(Th1) pathway were documented in up to 40% of children with
disseminated primary TB [7]. Among these, primary immun-
odeficiencies resulting from mutations in several genes, such as
complete IFNGR1, IFNGR2, IL12B, IL12BR1, STAT1, IRF8 and
TABLE 1. Documented genetic polymorphisms and host factors predisposing to infections due to intracellular bacteria
Pathogens Population Documented polymorphisms or host factors
Mycobacterium tuberculosis Adults and children MSMD (IFNGR1, IFNGR2, IL12B, IL12BR1, STAT1, IRF8, ISG15 receptor defects)
HLA (HLA-DR2, HLA-DQB1)
TLR1, TLR2
VDR
NRAMP1 (alias SLC11A1)
GWAS
Chlamydia pneumoniae, Chlamydia psittaci Adults Il-6-174G/C
Low-mannose binding (MBL)-2
Immunity-related GTP-ases (IRGs)
Chlamydia trachomatis Adults and children Pathogen recognition: TLRs (2,4,9), NODs (1,2), CD14, CCR5, CXCR5, MBL/MBP
Cytokines: ILs (1b, 1RN, 2, 4, 4R, 6, 10, 12B), IFNc, TNFa, TGF-b, LTA
Other: HLA (A, B, C, CW, DQA, DQB, DR), MMP9, IjBa, IjBL, TRAILR1
Mycoplasma pneumoniae Children Il-4 levels
Ratio Il-4/IFN-c
Coxiella burnetii Adults Il-10 overproduction leading to defective monocyte and phagosome maturation
T. whipplei Adults Decreased Th1 and Th17 reactivity
MSMD, Mendelian susceptibility to mycobacterial disease; HLA, human leucocyte antigen; TLR1, TLR2, Toll-like 1 and 2 receptors; VDR, vitamin D receptor; NRAMP1 (alias
SLC11A1), specific macrophage protein 1 (NRAMP1) gene polymorphisms; GWAS, genome-wide linkage analysis; Il, interleukin; IFN, interferon.
No documented polymorphism/host factors for Bartonella spp.
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ISG15IL, were documented in children with disseminated TB
disease [14–17]. Polygenic somatic and germinal mutations,
such as HLA polymorphisms (HLA-DR2 and HLA-DQB1), as
well as mutations in Toll-like 1 and 2 receptors (TLR1, TLR2)
and genes coding for the vitamin D receptor (VDR) may be
incriminated in reactivated pulmonary TB in adults, although
no convincing evidence has been provided so far [18–23]. In
contrast, various studies supported the role of specific
macrophage protein 1 (NRAMP1) gene polymorphisms in
pulmonary TB, with a heterogenous effect across populations
(African, Asian populations vs European populations), epide-
miological settings, clinical phenotypes and age at onset of TB
[24]. A recent meta-analysis [24] correlated NRAMP1 poly-
morphisms with pulmonary TB in African and Asian popula-
tions but not those of European descent [25,26]. A stronger
genetic effect associated with early-onset disease was sup-
ported by the documentation of numerous NRAMP1 alleles in
children whereas only a few were recovered from adult
patients [26]. Early-onset pulmonary TB was also associated
with variants of the TOX gene involved in the development of
CD4+ T cells [27–29].
A recent GWAS conducted among populations from
Gambia and Ghana identified a ‘gene desert’ on chromosome
18 as a risk factor for pulmonary TB and a second locus on
chromosome 11p13 as protective against TB [30]. These
associations were not consistent when repeated in other
populations [31,32], thus suggesting that GWAS may have a
limited impact on predisposition to adult pulmonary TB, at
least when considered as a single phenotype. In conclusion, the
exact nature of genetic factors involved in TB remains
unknown. Genetic heterogeneity together with a complex
mode of inheritance and other factors such as the intensity of
exposure to TB and variable M. tuberculosis strain virulence
may also have an impact on the clinical course of TB [26,33].
Chlamydia trachomatis
Genetic polymorphism may also affect clinical outcomes
resulting from infections due to intracellular bacteria and
other fastidious organisms such as Chlamydia spp. The genus
Chlamydia comprises three important human pathogens.
C. trachomatis causes blinding trachoma [34–36] and sexu-
ally-transmitted infections, whereas Chlamydia pneumoniae is
associated with asthma and community-acquired pneumonia
[37] and Chlamydia psittaci may cause severe respiratory
systemic zoonotic infections [36].
Host genetic markers seem to be the most promising
biological indicators of complicated chlamydia infection at
present [38–47]. Recent studies have led the way in
identifying genetic biomarkers useful for distinguishing women
with a past chlamydia infection and higher probability of
developing complications from women with an uncomplicated
chlamydia infection cleared without late complications. The
relevance of studying host genetic markers as well as
behavioural markers linked to acquiring chlamydia infection
has been shown by recent research on C. trachomatis strains
that cause trachoma. Bailey et al. [47] found that up to 40%
of the host-response to chlamydia infection in Gambian twin
pairs is based on host genetics. They estimated the relative
contribution of host genetics within the total variation in
lymphoproliferative responses (specific T-cell immune
responses) to C. trachomatis antigen. The scarring of the
cornea (trachoma) and the scarring of the fallopian tubes
(sexually transmitted chlamydia infection) have a remarkable
immunogenetic similarity. This has been summarized in a
recent review [40] which documented identical single nucle-
otide polymorphisms (SNPs) in ocular and tubal scarring for
such as IL-10, TNF-alpha and HLA types. In addition,
mannose-binding lectin gene polymorphism (MBL) has previ-
ously been described for ocular scarring.
SNP biomarkers have already shown a high predictive
value for the development of tubal pathology after being
exposed to Chamydia trachomatis. Thus, MBL was also
associated with tubal pathology development. Recent work
explored whether genetic traits (carrying multiple SNPs in
different genes) in the bacterial sensing system are associated
with an aberrant immune response and subsequently with
tubal pathology following a C. trachomatis infection. In one of
those studies the authors assessed in sub-fertile women the
TABLE 2. Characteristics of the most important observational studies included in the review of Mycobacterium tuberculosis
Author Year Country Population Polymorphisms
Boisson-Dupuis et al. [15] 2011 France Children Il-12Rb1 deficiency
Gao et al. [20] 2010 China Adults VDR polymorphism: FokI ff genotype, BsmI bb genotype, Taq1, ApaI
Li et al. [25] 2006 China Adults NRAMP1 (alias SLC11A1)
Malik et al. [26] 2005 Canada Adults and children NRAMP1 (alias SLC11A1)
Greenwood et al. [33] 2000 Aboriginal Canadians Adults and children NRAMP1 (alias SLC11A1)
Ma et al. [22] 2007 UK Adults TLR1, TLR2
Vejbaesya et al. [23] 2002 Thailand Adults HLA (HLA-DR2, HLA-DQB1)
Thye et al. [30] 2010 Ghana, Gambia Adults and children GWAS: chromosome 18q11.2
Nb, number; MSMD, Mendelian susceptibility to mycobacterial disease; HLA, human leucocyte antigen; TLR1, TLR2, Toll-like 1 and 2 receptors; VDR, vitamin D receptor;
NRAMP1 (alias SLC11A1), specific macrophage protein 1 (NRAMP1) gene polymorphisms; Il, interleukin; IFN, interferon; GWAS, genome-wide linkage analysis.
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presence of five single nucleotide polymorphisms (SNPs) in
five genes, all encoding for pattern recognition receptors
(PRRs) involved in sensing bacterial components. The SNPs
were chosen based on functional consequences they had for
these genes; for instance, the genetic variation in the NOD2
gene resulted in a shorter protein due to a stop codon
introduced by the SNP. It was shown that sub-fertile women
with serological evidence of prior chlamydia infection (IgG)
and two or more of these SNPs had a significantly higher
chance of developing pathology than women with fewer or
no SNPs [40]. This study shows the potential of host genetic
markers as indicators of the risk of late complications from
chlamydia infection in women. This type of biomarker could
be applied in better triage of women screened by the
gynaecologist for subfertility and laparoscopy (Fig. 1) [38].
Recently, at the Thirteenth International Symposium on
Human Chlamydial Infections (June 2014), two preliminary
key studies were presented. The first by Roberts and
colleagues [A] used for the first time a genome wide
association study (GWAS) to scan for pathway-wide genomic
differences between cases of scarring trachoma and controls.
Based on the polygenic character of infectious diseases,
meaning that each gene contributes a small proportion of the
overall heritability, they used pathway of distinction analysis
(PODA) to test for associations between groups of SNPs,
focusing on functional genes and gene-to-pathway associa-
tions. The top 15 SNPs had p-values between 10E-8 and
10E-5. By gene ontology (GO) analyses, many pathways were
identified, from which the most prominent were pathways
related to mitosis, the microtubale cytoskeleton, cell-cell
junctions and hormone-mediated signalling. The ongoing
study will be extended by validation in a second case-control
cohort, further in vitro analysis and system biology-based
analyses.
The second study was presented by Byrne and colleagues
[B]. They worked with an accurate forward genetic tool by
using an advanced recombinant inbred mouse strain set to
identify sets of genes associated, among others, with upper
genital tract complications. Oviduct disease severity was linked
to 17 candidate genes on chromosome 3 of mice, showing
synteny in part with orthologous genes on human chromo-
some 1. Similar results were obtained with 19 candidate genes
on mouse chromosome 19, showing synteny in part with
orthologous genes on human chromosome 9. The use of this
advanced recombinant inbred mouse is a major new tool to
help discovery of genes linked to susceptibility to and severity
of C. trachomatis disease.
All the above findings in the field of immunogenetics,
genetics and genomics of C. trachomatis infections are of
high relevance for public health and healthcare in general
[39,41]. These results will contribute to the understanding of
chlamydial infection, which is strongly associated with ectopic
pregnancy, tubal infertility, pelvic inflammation and miscarriage
[48]. Furthermore, these findings provide new insights into the
pathways that help explain individual heterogeneity in the
clinical course of C. trachomatis infection and the possible
development of more targeted and personalized approaches in
the prevention, diagnosis and treatment of disease, especially
in subfertility diagnosis.
C. pneumoniae and C. psittaci
Chlamydia pneumoniae may result in a wide spectrum of acute
respiratory conditions such as community-acquired pneumonia
(CAP), bronchitis [49,50] and pharyngitis. Recent evidence also
suggests its association with chronic conditions such as chronic
FIG. 1. Triage of women screened by a gynaecologist for subfertility
and laparoscopy, with stars indicating decision points where host
genetic markers for a high risk of development of complications from
Chlamydia trachomatis infection could be applied. A good SNP trait in
combination with IgG CT+ could indicate no laparoscopy is indicated
(green bar), while a bad SNP trait and IgG CT- could mean a
laparoscopy is indicated (red bar). The SNP trait will have a ‘grey’ zone
(grey bar) in which no clear advice can be given, and the gynaecologist
has to decide based on the available clinical data.
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obstructive pulmonary disease (COPD), cystic fibrosis (CF)
[51] and asthma exacerbations [52,53], thus raising the
question of underlying host genetic susceptibility [50].
Indeed, recent in vitro studies suggested the role of
underlying genetic factors such as IL-6 -174G/C or low
mannose-binding (MBL) polymorphisms in the development of
chronic pulmonary conditions triggered by C. pneumoniae
[54,55]. Therefore, host factors may determine the nature of
C. pneumoniae infections (acute vs. chronic).
Chlamydia psittaci is associated with life threatening respira-
tory infections. The contribution of genetic polymorphism to
susceptibility to C. psittaci infections has recently been sup-
ported by the documentation of polymorphisms in the family of
immunity-related GTP diseases (IGR) in animal models [35].
Thus, genetic polymorphism may have an impact on the
susceptibility to infections caused by both Chlamydia pneumoniae
and psitacci, as well as the nature of the respiratory disease.
These findings should, however, be confirmed by using new
exome sequencing strategies and should be validated in a large
cohort of patients. Similar investigations should be carried out in
respiratory conditions resulting fromM. pneumoniae infections,
especially given its frequent documentation in CAP in children.
Mycoplasma pneumoniae
Mycoplasma pneumoniae infections are associated with a wide
spectrum of clinical entities, including mainly conjunctivitis and
respiratory diseases [56,57]. It is the most prevalent agent of
CAP in children above 2 years of age and has also been
associated with asthma exacerbations [52,53,58–60], recur-
rent wheezing episodes and acute bronchitis in children
[57,58]. More recent evidence suggests its role in CF
exacerbations [61]. As such, children presenting with these
conditions should systematically be screened for M. pneumo-
niae in addition to viral pathogens which are usually considered
as the main triggers for CF. In addition, M. pneumoniae has also
been associated with immune-mediated conditions [62–65],
resulting in erythema multiforma and reactive arthritis.
In vitro studies [62,63,65] have demonstrated that
M. pneumoniae-infected epithelial cells resulted in the induc-
tion of various cytokines and chemokines, including pro-inflam-
matory (tumour necrosis factor-a), type 1 (interferon-c) and
type 2 (interleukin-6) cytokines and a (interleukin-8) and
b-chemokines [63]. In summary, a predominant type 2-like
cytokine response results from M. pneumoniae infections, as
supported by experimental studies [65,66]. Thus, individuals
with stronger cytokine and cell-mediated immune responses
may experience more severe pulmonary injury, thus support-
ing the contribution of genetic polymorphisms [67,68].
Coxiella burnetii
Another agent of atypical pneumonia is C. burnetii, for which
there is more evidence of the importance of underlying host
polymorphisms. Coxiella burnetii, an obligate intracellular bac-
terium, is the causal agent of Q fever. It is prevalent worldwide
and highly infectious [2,69], being mainly transmitted by
inhalation of contaminated aerosols [70]. Infection generally
results in acute Q fever, which is symptomatic in <40% of cases
[2]. A small proportion (<5%) will present with severe disease
such as atypical pneumonia or granulomatous hepatitis. Less
frequently, pericarditis, meningo-encephalitis or arthritis may
also occur [1]. Chronic Q fever, mainly endocarditis, observed
among individuals with underlying predispositions (pregnancy,
immunosuppression or valvular defects), occurs months to
years after the acute episode and can result in significant
mortality rates (25–60%) [1]. Auto-immune conditions such as
Libman-Sacks endocarditis have been reported in patients with
documented C. burnetii infections [71]. The highest rates of
symptomatic Q fever are observed among men and children
above 15 years of age [72], suggesting a major role for human
genetic factors [73]. A more recent, a more recent study [4]
reported cases of hepatitis that resulted from exposure to
aerosols, thus reinforcing the contribution of other factors
such as host-related factors.
Immune control of C. burnetii results in granuloma forma-
tion and systemic cell-mediated immune responses, including
IFN-c- production, probably as a result of monocyte/macro-
phage migration and T lymphocyte recruitment [74–76].
Experimental studies have correlated defective monocyte
migration [74] and defective phagosome maturation resulting
from Il-10 overproduction [75,76] with ineffective granuloma
formation, a phenotype observed among patients with chronic
Q fever. These experimental findings strongly support the
contribution of underlying genetic polymorphisms.
Tropheryma whipplei
Like Coxiella, Tropheryma whipplei is an important agent of
blood culture-negative endocarditis. T. whipplei is generally
acquired through faeco-oral transmission. While T. whipplei is
found ubiquitously in the environment, it remains a rare
disease with an annual incidence below 1 per 1 000 000
population [77–79], suggesting the role of host factors.
Furthermore, a higher prevalence of the bacteria is reported
in men of European ancestry [78]. Also, T. whipplei can be
detected in as many as 35% of healthy carriers, thus reinforcing
the role of an underlying polymorphism in determining late
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disease onset [80]. The contribution of a genetic background
to the evolution of Whipple disease was recently supported by
the association of Whipple disease with human leukocyte
antigen alleles DRB1*13 and DQB1*06 [79,81,82]. A genetic
polymorphism in the cytokine genes was supported by the
documentation of low levels of TGF-b1 and high production of
Il-10, resulting in decreased Th1 and Th17 reactivity among
infected patients compared with healthy controls, although the
association was not significant [83]. Polymorphisms in the
cytokine genes should be further explored in larger cohorts,
ideally by exome sequencing.
Conclusion
Infectious diseases due to intracellular and/or fastidious
bacteria may have pleomorphic clinical presentations, partially
due to inter-individual variation in terms of polygenic genetic
susceptibility. To date, most gathered information has been
hypothesis driven. Thus, in the coming years, with the use of
exome sequencing, a new unexpected genetic locus might be
discovered.
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